Cargando…

Mutant p53 as an Antigen in Cancer Immunotherapy

The p53 tumor suppressor plays a pivotal role in cancer and infectious disease. Many oncology treatments are now calling on immunotherapy approaches, and scores of studies have investigated the role of p53 antibodies in cancer diagnosis and therapy. This review summarizes the current knowledge from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobhani, Navid, D’Angelo, Alberto, Wang, Xu, Young, Ken H., Generali, Daniele, Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312027/ https://www.ncbi.nlm.nih.gov/pubmed/32521648 http://dx.doi.org/10.3390/ijms21114087

Ejemplares similares

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2022)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
por: Sobhani, Navid, et al.
Publicado: (2020)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

MR1-Restricted T Cells in Cancer Immunotherapy
por: Flores-Villanueva, Pedro, et al.
Publicado: (2020)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
por: Chasov, Vitaly, et al.
Publicado: (2021)

Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Mutant p53 in Cancer Progression and Targeted Therapies
por: Zhu, Gaoyang, et al.
Publicado: (2020)

Targeting mutant p53 for cancer therapy
por: Oren, Moshe, et al.
Publicado: (2016)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
por: Kong, Li Ren, et al.
Publicado: (2020)

Editor's Note on ‘Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53’
Publicado: (2023)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

Structural and Drug Targeting Insights on Mutant p53
por: Gomes, Ana Sara, et al.
Publicado: (2021)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
por: Muller, Patricia A.J., et al.
Publicado: (2014)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Glycerol restores heat-induced p53-dependent apoptosis of human glioblastoma cells bearing mutant p53
por: Ohnishi, Takeo, et al.
Publicado: (2002)

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

Treating p53 Mutant Aggregation-Associated Cancer
por: Kanapathipillai, Mathumai
Publicado: (2018)

Mutant p53 as a guardian of the cancer cell
por: Mantovani, Fiamma, et al.
Publicado: (2018)

Mutant p53 in cancer therapy—the barrier or the path
por: Zhou, Xiang, et al.
Publicado: (2018)

Targeting mutant p53 stabilization for cancer therapy
por: Wang, Jiajian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_snadubu9fhjq809gptcn56jita